Merck & Co. reported Friday second-quarter earnings that rose to $1.21 billion, or 43 cents a share, from $687 million, or 24 cents a share, in the same period a year ago.
Advertisement
Merck & Co. Inc.is a global health care company.
The company said the strong dollar reduced sales by 2 percent, though those negative effects declined from recent years. Sales of Merck’s top selling drug, Januvia/Janumet, increased 2% to $1.63 billion, beating the FactSet consensus of $1.61 billion.
Back on 7/28/2015 the company’s estimated EPS value was $0.80 and it reported $0.86 earnings per share (EPS) for the quarter ended on 6/2015. (NYSE:MRK) announced its second quarter of fiscal year 2016 (2QFY16) earnings before the opening bell today. The company’s revenue was up.6% compared to the same quarter past year.
The company’s revenue rose 1 percent to $9.84 billion, above analysts’ average estimate of $9.78 billion. (NYSE:MRK) will report earnings per share of $0.91 in their quarterly report and it is expected to announce the company’s results on 7/29/2016 BMO. Keytruda drove the increase in oncology drug sales, surging from $110 million last year to $314 million this year.
They hope Keytruda, being tested against 30 tumor types, will become a backbone of the new generation of more-effective treatments for numerous cancers. Merck plans to release full details in the coming months of a study in which Keytruda prolonged survival in such patients, compared with chemotherapy.
Hepatitis C drug Zepatier, launched in January, posted sales of just $112 million.
Sales of veterinary medicines rose 7 percent, to $898 million. The full results should be published soon and Merck is working with US regulators, the company said in a conference call with analysts.
Sales of allergy treatment Nasonex fell 53% in the first quarter from the year prior. That’s reducing sales or slowing growth.
Advertisement
HPV vaccines Gardasil and Gardasil 9 fell 8% to $393 million due to the timing of public sector purchases. At the same time, Merck plans to start new laboratories in Cambridge, Mass., and the San Francisco Bay Area, as part of a trend among large drugmakers to try to tap into hot clusters of biotechnology startup activity and academic research. (NYSE:MRK). The most expectant earnings per share estimate of the stock is set at $3.77 while the conservative estimates kept at $3.66 over the current year. Inc.to earn $0.98 in earnings per share (EPS) on revenue of $9.79B.
